期刊
CLINICAL BREAST CANCER
卷 21, 期 2, 页码 143-152出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clbc.2021.03.007
关键词
Cancer immunotherapy; Metastatic breast cancer; Triple-negative breast cancer; Tumor microenvironment; Radiation oncology
类别
资金
- Cedars-Sinai Cancer
Breast irradiation has the potential to induce antitumor immune responses, and when combined with immune checkpoint blockade, it shows synergy in clinical settings. This has sparked substantial interest in combining radiation and immunotherapy to enhance immune responses for the treatment of breast cancer.
Breast irradiation has long been utilized in the adjuvant or metastatic setting to eliminate microscopic disease or to palliate existing disease, respectively. However, preclinical data have demonstrated that radiation can also alter the tumor microenvironment and induce antitumor immune responses. As a result, multiple clinical studies have been undertaken and have reported synergy between radiation and immune checkpoint blockade across various cancer types. Given recent clinical successes with immune checkpoint blockade in both early-stage and metastatic breast cancer, there has been substantial interest in combining radiation and immunotherapy to enhance local and systemic immune responses. Herein, we review the preclinical rationale for combining radiotherapy and immunotherapy, the early clinical trials that have adopted this strategy in breast cancer, and the landscape of ongoing relevant clinical trials. Finally, we propose future directions based on promising preclinical studies that integrate radiation, checkpoint blockade, and novel agents for the treatment of breast cancer. (C) 2021 The Authors. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据